Shield Therapeutics plc (LON:STX – Get Free Report)’s share price dropped 11.5% on Tuesday . The company traded as low as GBX 5.19 and last traded at GBX 5.40. 11,462,072 shares changed hands during trading, an increase of 382% from the average session volume of 2,379,675 shares. The stock had previously closed at GBX 6.10.
Shield Therapeutics Stock Performance
The firm has a market capitalization of £57.75 million, a price-to-earnings ratio of -2.70 and a beta of 1.72. The company has a debt-to-equity ratio of -146.28, a current ratio of 0.75 and a quick ratio of 2.16. The firm has a 50 day moving average price of GBX 5.38 and a 200-day moving average price of GBX 7.08.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Read More
- Five stocks we like better than Shield Therapeutics
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
